Which has higher earnings and valuation, SCPS or CLVR?

Scopus BioPharma has higher earnings, but lower revenue than Clever Leaves. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scopus BioPharma N/A N/A -$11.61M N/A N/A Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A

Is SCPS or CLVR more profitable?

Company Net Margins Return on Equity Return on Assets Scopus BioPharma N/A N/A N/A Clever Leaves N/A N/A N/A

Is CLVR or VRPX more profitable?

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Virpax Pharmaceuticals N/A -1,554.34% -338.29%

Which has higher earnings & valuation, CLVR or TRVN?

Clever Leaves has higher revenue and earnings than Trevena. Clever Leaves is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A Trevena $443K 0.02 -$40.29M -$47.04 N/A

Is CLVR or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Trevena N/A N/A -119.55%

Is CLVR or NAVB more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A

Is PXMD or CLVR more profitable?

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity. Company Net Margins Return on Equity Return on Assets PaxMedica N/A -3,167.89% -560.35% Clever Leaves N/A N/A N/A

Clever Leaves (CLVR) Competitors

$0.01 0.00 (0.00%)

As of 07/24/2026

Compare

CLVR vs. SCPS, VRPX, TRVN, NAVB, and PXMD

Should you buy Clever Leaves stock or one of its competitors? MarketBeat compares Clever Leaves with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clever Leaves include Scopus BioPharma (SCPS), Virpax Pharmaceuticals (VRPX), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.

How does Clever Leaves compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Scopus BioPharma has higher earnings, but lower revenue than Clever Leaves.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

6.9% of Clever Leaves shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Scopus BioPharma has a beta of -0.25, indicating that its stock price is 125% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its stock price is 381,513% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Scopus BioPharma	N/A	N/A	N/A
Clever Leaves	N/A	N/A	N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Scopus BioPharma	Neutral
Clever Leaves	Neutral

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Virpax Pharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Virpax Pharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Virpax Pharmaceuticals	Neutral

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Clever Leaves has a beta of 3816.13, meaning that its stock price is 381,513% more volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of -16.52, meaning that its stock price is 1,752% less volatile than the broader market.

Summary

Clever Leaves beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does Clever Leaves compare to Trevena?

Clever Leaves (NASDAQ:CLVR) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Trevena	Neutral

Clever Leaves has higher revenue and earnings than Trevena. Clever Leaves is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Trevena	$443K	0.02	-$40.29M	-$47.04	N/A

Clever Leaves has a beta of 3816.13, suggesting that its stock price is 381,513% more volatile than the broader market. Comparatively, Trevena has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Clever Leaves beats Trevena on 6 of the 9 factors compared between the two stocks.

How does Clever Leaves compare to Navidea Biopharmaceuticals?

Clever Leaves (NASDAQ:CLVR) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Navidea Biopharmaceuticals	N/A	N/A	N/A

Clever Leaves has a beta of 3816.13, suggesting that its stock price is 381,513% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Navidea Biopharmaceuticals	Neutral

6.9% of Clever Leaves shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.2% of Clever Leaves shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Clever Leaves beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks.

How does Clever Leaves compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Clever Leaves' return on equity of 0.00% beat PaxMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PaxMedica	N/A	-3,167.89%	-560.35%
Clever Leaves	N/A	N/A	N/A

Clever Leaves has higher revenue and earnings than PaxMedica. Clever Leaves is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PaxMedica	N/A	N/A	-$18.29M	-$6.09	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

PaxMedica has a beta of -0.99, indicating that its stock price is 199% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its stock price is 381,513% more volatile than the broader market.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
PaxMedica	Neutral
Clever Leaves	Neutral

Summary

Clever Leaves beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLVR vs. The Competition

Export

Metric	Clever Leaves	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18K	$975.85M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	0.00	1.53	27.14	23.64
Price / Sales	0.00	104.46	517.08	89.45
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	0.00	8.47	10.28	6.07
Net Income	-$17.90M	-$2.70M	$3.60B	$331.99M
7 Day Performance	N/A	-2.29%	-1.27%	-0.63%
1 Month Performance	N/A	-3.97%	-0.37%	-2.00%
1 Year Performance	N/A	27.39%	18.30%	13.62%

Clever Leaves Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLVR Clever Leaves	N/A	$0.01 flat	N/A	+3,250.0%	$18K	$17.42M	N/A	560
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+66.7%	$21K	N/A	N/A	9
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	-99.5%	$14K	N/A	N/A	7
TRVN Trevena	N/A	$0.01 flat	N/A	-98.8%	$11K	$443K	N/A	40	Gap Up
NAVB Navidea Biopharmaceuticals	N/A	N/A	N/A	N/A	$10K	$8.13K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clever Leaves (CLVR) Competitors

CLVR vs. SCPS, VRPX, TRVN, NAVB, and PXMD

How does Clever Leaves compare to Scopus BioPharma?

Summary

How does Clever Leaves compare to Virpax Pharmaceuticals?

Summary

How does Clever Leaves compare to Trevena?

Summary

How does Clever Leaves compare to Navidea Biopharmaceuticals?

Summary

How does Clever Leaves compare to PaxMedica?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLVR vs. The Competition

Clever Leaves Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clever Leaves (CLVR) Competitors

CLVR vs. SCPS, VRPX, TRVN, NAVB, and PXMD

How does Clever Leaves compare to Scopus BioPharma?

Which has higher earnings and valuation, SCPS or CLVR?

Do institutionals and insiders believe in SCPS or CLVR?

Which has more volatility & risk, SCPS or CLVR?

Is SCPS or CLVR more profitable?

Does the media favor SCPS or CLVR?

Summary

How does Clever Leaves compare to Virpax Pharmaceuticals?

Is CLVR or VRPX more profitable?

Which has stronger earnings and valuation, CLVR or VRPX?

Does the media refer more to CLVR or VRPX?

Do institutionals and insiders have more ownership in CLVR or VRPX?

Which has more volatility and risk, CLVR or VRPX?

Summary

How does Clever Leaves compare to Trevena?

Does the media favor CLVR or TRVN?

Which has higher earnings & valuation, CLVR or TRVN?

Which has more risk & volatility, CLVR or TRVN?

Is CLVR or TRVN more profitable?

Do insiders and institutionals believe in CLVR or TRVN?

Summary

How does Clever Leaves compare to Navidea Biopharmaceuticals?

Which has higher earnings & valuation, CLVR or NAVB?

Is CLVR or NAVB more profitable?

Which has more risk & volatility, CLVR or NAVB?

Does the media favor CLVR or NAVB?

Do insiders and institutionals believe in CLVR or NAVB?

Summary

How does Clever Leaves compare to PaxMedica?

Do insiders & institutionals have more ownership in PXMD or CLVR?

Is PXMD or CLVR more profitable?

Which has better valuation and earnings, PXMD or CLVR?

Which has more risk & volatility, PXMD or CLVR?

Does the media refer more to PXMD or CLVR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLVR vs. The Competition

Clever Leaves Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools